Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Irene Boswell

Internal Medicine Rockford, IL Medical Doctor

NPI 1548226905 CMS profile 69184

7520 Blairmore Dr, Rockford, IL 61107

Open in the dashboard

General payments

$10,374

675 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Irene Boswell of Rockford, IL is reported in the CMS Open Payments database as having received $10,374 across 675 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $2,508 144
2022 General $2,150 136
2021 General $1,970 117
2020 General $1,748 125
2019 General $1,998 153

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Irene Boswell
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Irene Boswell were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Irene Boswell Internal Medicine median Middle half National median
2019 $1,998 $159 $48–$570 $163
2020 $1,748 $119 $33–$402 $114
2021 $1,970 $135 $37–$521 $132
2022 $2,150 $141 $42–$496 $149
2023 $2,508 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. AstraZeneca Pharmaceuticals LP $1,313 58 payments
  2. AbbVie, Inc. $1,117 75 payments
  3. Novo Nordisk Inc $867 68 payments
  4. Amgen Inc. $692 48 payments
  5. Lilly USA, LLC $621 57 payments
  6. GlaxoSmithKline, LLC. $544 28 payments
  7. Pfizer Inc. $452 30 payments
  8. Amarin Pharma Inc. $451 25 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $427 33 payments
  10. Janssen Pharmaceuticals, Inc $407 32 payments
  11. Other $3,485 221 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $10,241 670 payments
  2. Education $133 5 payments
Products named General payments · program years 2019–2023
  1. FARXIGA $981 38 payments
  2. Ozempic $524 42 payments
  3. TRELEGY ELLIPTA $521 27 payments
  4. UBRELVY $508 34 payments
  5. Repatha $502 33 payments
  6. XARELTO $378 30 payments
  7. JARDIANCE $350 33 payments
  8. RYBELSUS $325 25 payments
  9. Vascepa $286 17 payments
  10. JANUVIA $284 26 payments
  11. Other $9,648 665 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

389

Median for Internal Medicine: 777

Drug cost

$4,432

Median for Internal Medicine: $73,373

Branded share of claims

10%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 87 $922
Albuterol Sulfate Hfa Albuterol Sulfate Brand 11 $383
Ezetimibe Generic 19 $348
Rosuvastatin Calcium Generic 46 $347
Liothyronine Sodium Generic 11 $331
Tamsulosin Hcl Generic 14 $329
Pantoprazole Sodium Generic 12 $285
Amlodipine Besylate Generic 33 $237
Atorvastatin Calcium Generic 34 $235
Metoprolol Succinate Generic 22 $226

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

675 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record